What it's actually good for
Apigenin is a flavonoid concentrated in chamomile flowers, along with smaller amounts in parsley and celery. Its reputation as a sleep and relaxation aid comes from a specific mechanism: Viola et al. (1995) showed it competitively binds the benzodiazepine site on GABAA receptors, producing anxiolytic effects in mice without the sedation seen with classical benzodiazepines. That's a real, well-characterized mechanism — but it's a mouse study. Isolated apigenin, at the doses sold in supplements, has essentially no dedicated human trials. What human data exists comes from chamomile extract, a whole-plant preparation containing apigenin alongside dozens of other compounds, at doses far below what a 50-100 mg apigenin capsule delivers.
What the research says
Relaxation and sleep support (Grade C). The mechanistic case is solid — apigenin binds GABA receptors the way anti-anxiety drugs do. The human case is not. A 2011 randomized placebo-controlled pilot trial (Zick et al., BMC Complement Altern Med) tested a chamomile extract standardized to roughly 3.9 mg of apigenin per dose in adults with chronic insomnia and found no statistically significant improvement over placebo in total sleep time or sleep efficiency — only modest, non-significant trends in sleep latency and nighttime awakenings. That's a null-ish result, and it used a fraction of the apigenin found in typical supplements, so it doesn't rule out an effect at higher isolated doses — it just means nobody has shown one.
Anxiety (not a formal claim here, but relevant). A separate randomized trial (Amsterdam et al., 2009, J Clin Psychopharmacol) gave chamomile extract standardized to 1.2% apigenin to adults with generalized anxiety disorder and found a statistically significant, if modest, reduction in anxiety scores versus placebo (P = 0.047) over 8 weeks. This is the closest thing to positive human evidence in the apigenin literature, and it's still whole-plant chamomile, not the isolated compound.
Neuroprotection and cognition. The oneLine and marketing around apigenin lean heavily on neuroprotective potential — reduced neuroinflammation, antioxidant activity, effects on aging-related gene expression. All of that is preclinical: cell and animal work only. There are no completed human trials testing apigenin for cognitive performance or neuroprotection. Treat this as a research direction, not a benefit you can expect.
Apigenin also has a substantial cancer-chemoprevention literature (Shukla & Gupta, 2010, Pharm Res) — mostly epidemiological association and preclinical mechanism, with the authors explicitly noting no human supplementation trials existed. That's interesting biology, not a reason to take it for sleep.
How much, and which form
Typical supplement doses run 50-100 mg of isolated apigenin before bed. Worth noting: this is 10-20x the apigenin dose used in the human chamomile trials above, which tested extracts delivering single-digit milligrams. That gap is unexplored territory — not necessarily unsafe, but not validated either.
Safety & interactions
Apigenin's safety track record leans on chamomile's long history of use as tea and extract, which is reassuring but not the same as safety data on isolated, high-dose apigenin. It may cause drowsiness, and it can theoretically compound sedatives or benzodiazepines given the shared GABA mechanism. At high concentrations it may inhibit CYP1A2 and CYP2C9, enzymes involved in metabolizing several common medications. This is informational, not medical advice — check with a clinician before starting, especially if you're on sedatives, benzodiazepines, or drugs metabolized by those enzymes.
How we picked the brand
An apigenin product earns a spot when it's isolated, accurately dosed, and third-party tested — apigenin supplements vary widely in purity, and chamomile-derived extracts don't always disclose actual apigenin content. NSF Certification for Sport was the deciding factor here given the thin safety data at supplement doses.